Table 3.

Hazard Ratio for the Development of BRCA-Associated Gynecologic Cancer After RRSO

Mutation	No. of Patients	No. of Women Electing RRSO	Mean FU (months)	No. of Gynecologic Cancers After RRSO	No. of Women Electing Surveillance	Mean FU (months)	No. of Gynecologic Cancers During Surveillance	Hazard Ratio	95% CI	P
BRCA1 and BRCA2	792	509	40.3	3	283	37.6	12	0.12	0.03 to 0.41	.001
BRCA1	498	325	41.1	3	173	40.1	10	0.15	0.04 to 0.56	.005
BRCA2	294	184	39.0	0	110	33.7	2	0.00	Not estimable

Abbreviations: RRSO, risk-reducing salpingo-oophorectomy; FU, follow-up.